InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.26
(
0.00%
)
US TECH 100
19,251.60
(
2.09%
)
Dow Jones
41,503.10
(
0.00%
)
Brent Oil
74.06
(
2.31%
)
Bitcoin
62,930.73
(
2.04%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12534
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: LUMA14 post# 75780

Saturday, 08/27/2016 5:58:32 AM

Saturday, August 27, 2016 5:58:32 AM

Post# of 80490
"Conclusions:
With a longer follow-up, the newer TKIs remain more potent than imatinib, **yet with no significant effect on survival. **As CMR is a prerequisite for treatment discontinuation and cure, the newer TKIs favor treatment cessation."

That is counter to what Ariad has discovered with Iclusig. Some patients are still on Iclusig after many years..

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up